Search results
Bristol-Myers Squibb Co (BMY) Q1 2024 Earnings Report: A Detailed Overview
GuruFocus.com via Yahoo Finance· 4 minutes agoRevenue: Reported at $11.9 billion, up 5% year-over-year, exceeding the estimate of $11.457 billion....
Bristol Myers Squibb Posts Loss In Q1; Updates 2024 Non-GAAP EPS Guidance
RTT News· 2 hours agoBristol Myers Squibb (BMY) posted a first quarter net loss attributable to Bristol Myers Squibb of $11.9 billion, or $5.89 per share, compared to net income of $2.
Bristol Myers posts quarterly loss, revenue rises 5%
KFGO· 47 minutes agoBy Deena Beasley (Reuters) - Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics ...
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
NBC Connecticut· 2 hours agoBristol Myers Squibb reported first-quarter revenue that topped expectations as its blockbuster...
Bristol-Myers stock falls despite Q1 beat (NYSE:BMY)
Seeking Alpha· 1 hour agoBristol-Myers Squibb (BMY) stock dips even as the company topped consensus with Q1 2024 results, despite headwinds in its growth portfolio. Read more...
Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates
Market Watch· 2 hours agoBristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by...
Bristol-Myers Squibb stock slips despite earnings beat
Investing.com· 8 hours agoBristol-Myers Squibb stock slips despite earnings beat
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 9 hours agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024
FierceBiotech· 36 minutes agoBristol Myers Squibb is the latest large pharma to wield the restructuring ax, with plans to cut $1.5 billion in costs by the end of 2025, including laying off more than 2,000 employees. The ...
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss
Morningstar· 1 hour agoBy Rob Curran Bristol-Myers Squibb cut its 2024 earnings projection even as the drug giant posted a narrower-than-anticipated first-quarter loss, reflecting the impact of product acquisitions for a company with a number of popular pharmaceuticals
